Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma Resource Center

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use